We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca has agreed to buy San Mateo, Calif.-based ZS Pharma, a seven-year-old company whose hyperkalemia candidate ZS-9 could prove to be a blockbuster, in a deal valued at about $2.7 billion. Read More
French drugmaker Sanofi is looking to future-proof its diabetes franchise by in-licensing rights to a trio of next-generation diabetes medicines from South Korea’s Hanmi in a deal worth up to $4.2 billion. Read More
The Federal Court of Canada has quashed Health Canada’s import ban on drugs from two Apotex facilities in India, saying the agency proceeded unfairly. Read More
Mylan may move forward with its proposed hostile takeover bid of Perrigo, as long as it divests seven generic drugs, the FTC has determined. The move is the final regulatory hurdle for Mylan’s bid and eases the FTC’s concerns that the deal would harm competition. Read More
A new EvaluatePharma report projects the orphan drug market will surge over the next five years, doubling the yearly growth of the overall prescription drug market. Read More
Valeant is offering patients access to its dermatology products for zero dollar copay under a program through major pharmacy chains and independent pharmacies. Read More